There are several small-molecule inhibitors of TRK tyrosine kinases at various stages of clinical development and regulatory approval, some of which target multiple kinases, such as entrectinib, TPX-0005, and DS-6051b, and one of which, larotrectinib, is specific for TRK kinases. Published ...